Significance and Impact of the Study: This study demonstrated the first successful expression of a codon-optimized gene coding for enterovirus 71 viral capsid protein 1 (EV71-VP1) in Bifidobacterium pseudocatenulatum M115, a novel probiotic strain isolated from human intestines. The EV71-VP1 was constitutively expressed under the control of P919 promoter derived from B. bifidum BGN4 in the cytoplasm of bacterial cells supporting the use of heterologous promoter and terminator sequences for viral gene expression in Bifidobacterium species.
Introduction
Bifidobacterium species constitute one of the major bacterial populations in the human gastrointestinal tract and are able to be beneficial to human health (Reuter 2001; Park et al. 2002; Gleinser et al. 2012) . These benefits include modulation of immune responses (Tsai et al. 2012) , production of bioactive substances to inhibit certain pathogens (Chenoll et al. 2011) , increasing anticarcinogenic activities (Rafter et al. 2007) , and enhancement of response to vaccines (Rizzardini et al. 2012) . Some Bifidobacterium strains have been proven to be probiotics, live micro-organisms that provide health benefits to hosts when ingested in adequate amounts (Gibson et al. 2017) , such as Bifidobacterium breve M-16V, B. longum BB53 and B. lactis HN019 (Enomoto et al. 2014; Bernini et al. 2016) . For these reasons, Bifidobacterium species with beneficial effects are attractive candidates for the development of model strains for expression of antigens derived from pathogens. These strains would elicit mucosal immunity against a particular pathogen, such as recombinant B. animalis expressing flagellin of Salmonella may be Letters in Applied Microbiology 68, 9--16 © 2018 The Society for Applied Microbiology effective against Salmonella enterica infections (Takata et al. 2006; Trombert 2015) .
To date, several recombinant bifidobacterial strains expressing immunogenic antigens derived from viruses and pathogenic bacteria have been constructed and used for immunization in animal models against the corresponding infectious diseases (Takata et al. 2006; Takei et al. 2014) . Many biologically active proteins such as interleukin 10 and tumor-associated antigens have also been expressed in Bifidobacterium sp. (Khokhlova et al. 2010; Kitagawa et al. 2017) . For these purposes, bifidobacterium-based cloning and expression systems have already been developed, leading to the generation of particular recombinant Bifidobacterium strains (Sun et al. 2012) . A number of expression vectors based on constitutive and inducible promoters have been constructed for the expression of homologous and heterologous proteins in Bifidobacterium species. As such, promoters derived from the histone-like protein coding gene (hup) from B. longum (Hamaji et al. 2007) , the glyceraldehyde 3-phosphate dehydrogenase gene (gap) from Bifidobacerium bifidum (Sun et al. 2014) , the elongation factor P gene from B. longum (Montenegro-Rodriguez et al. 2015) , the a-amylase gene from B. adolescentis (Ma et al. 2012) , and the 16S rRNA gene from B. longum (Park et al. 2008) have been successfully used for heterologous gene expression in bifidobacteria species. Recently, microarray analysis demonstrated that P919 promoter, which drives the expression of large ribosomal protein (encoded by the rplM gene) of B. bifidum BGN4, showed the highest efficiency for controlling the expression of b-glucosidase in both B. bifidum BGN4 and Escherichia coli DH5a (Wang et al. 2012; You et al. 2015) . However, the use of this promoter for the control of gene expression in other Bifidobacterium species has yet to be reported. Therefore, this promoter is an attractive candidate for foreign gene expression in bifidobacteria, especially genes encoding immunogenic proteins from pathogens.
This study aimed to determine heterologous expression of enterovirus-71 capsid protein 1 (EV71-VP1) in B. pseudocatenulatum M115, a probiotic strain isolated from human intestines that was successfully used as a host for heterologous expression of bifidobacterial alpha-arabinofuranosidase ( Alvarez-Mart ın et al. 2008; Delgado et al. 2008) . EV71-VP1 has been demonstrated to elicit protective neutralizing antibodies, which results in prevention of EV71 infection. Thus, the antigen is an appropriate candidate for EV71 vaccine formulation (Tian et al. 2012) . To this end, a constitutive bifidobacterial promoter was used to control the gene expression. The expression cassettes developed in this study may be a valuable tool for the expression of heterologous genes in this genus. Furthermore, the recombinant proteins may be used for immunization in animal models.
Results and discussion
Enterovirus 71 (EV71) is the second most common cause of hand, foot, and mouth disease (HFMD), a highly contagious viral infection affecting young children. Symptoms of HFMD are usually mild, but uncommon and fatal neurological or cardiac complications, such as meningitis and acute flaccid paralysis, may develop (Yi et al. 2017) . Several types of EV71 vaccines candidates, such as attenuated and inactivated whole-virus, recombinant proteins, and others, have already been proposed (Yi et al. 2017) . However, efficacy of most vaccines against different EV71 genotypes spread worldwide has yet to be reported. Therefore, development of alternative vaccines is still needed; especially mucosal vaccines, as this administration route can elicit protective immunity at both local and systemic levels (Medina and Guzman 2001) . The EV71-VP1 protein is a potent immunogen that induces protective neutralizing antibodies and confers protection against EV71 infection (Tian et al. 2012) .
At present, beneficial probiotic effects of several strains of Bifidobacterium species in humans have been proven and documented (Picard et al. 2005; Russell et al. 2011) . One of these beneficial effects is bifidobacteria strains can be constructed as an alternative cell factory for the production of valuable proteins for industrial and medical applications. Although several antigens derived from bacteria, viruses and tumour-associated proteins have successfully been expressed in some Bifidobacterium species, including B. longum and B. breve (Takata et al. 2006; Takei et al. 2014; Kitagawa et al. 2017) , appropriate cloning and expression systems are still needed to generate functional recombinant strains. One main factor affecting the translational efficiency of heterologous genes in a bacterial host is recognition of codons by the host tRNAs (Pouwels and Leunissen 1994) . Therefore, adaptation of codon usage in a host is pivotal for the expression of heterologous genes. Codon optimization for increased protein expression in B. longum, such as expression of alpha-melanocyte-stimulating hormone (Wei et al. 2016) , antigenic fragments of viral proteins (Shkoporov et al. 2015) , hepatitis C virus non-structural protein (Takei et al. 2014) , and Wilms' tumor 1 protein (Kitagawa et al. 2017) , has been described. Hence, this strategy was adopted in this study for the expression of EV71-VP1 in B. pseudocatenulatum. Codon analysis of the native nucleotide sequence of ET71-VP1 indicated rare codons as observed in the B. pseudocatenulatum genome. These codons were 5 ATA coding for isoleucine, 3 TTA coding for leucine and 3 CGG coding for arginine. For optimization, all these rare codons were replaced with frequently used codons in B. pseudocatenulatum. These modifications included replacement of ATA, TTA, and CGG with ATC, Letters in Applied Microbiology 68, 9--16 © 2018 The Society for Applied Microbiology CTG, and CGC respectively. The optimized codons of ET71-VP1 gene are summarized in Table 1 . Finally, the 891-bp DNA segment of the codon-optimized ET-VP1 gene was synthesized, cloned into pUC19, and the construct was designated as pUCIDT-VP1. In addition to codon optimization, a functional promoter is needed to control gene expression. Compared to inducible promoters, constitutive promoters do not need inducers (chemical or bioactive compounds) for expression. As previously demonstrated, the constitutive P919 promoter derived from B. bifidum BGN4 showed high expression efficiency of b-glucosidase in both B. bifidum BGN4 and E. coli DH5a (Wang et al. 2012) . Moreover, the P919 promoter has been used to overproduce b-glucosidase in soy fermentation (You et al. 2015) . Therefore, this promoter was selected to drive the expression of the ET71-VP1 gene. To avoid unwanted downstream transcription, the rho-independent terminator (TT) derived from the peptidase N gene of Lactococcus lactis was incorporated downstream to the ET71-VP gene sequence.
Steps undertaken to construct the expression vector containing the codon-optimized ET71-VP1 gene are graphically shown in Fig. 1 . The P919 promoter fragment was amplified from the synthetic ProSP nucleotide sequence and cloned into pUCIDT-VP1 vector at the 5 0end of ET71-VP1 gene, resulting in the construct pUCIDT-P919-VP1. Similarly, the TT of L. lactis was amplified from pLC13Á9-Ldh-M2e:HBc-TT and cloned immediately downstream of the ET71-VP1 gene in pUCIDT-P919-VP1 to generate the construct pUCIDT-P919-VP1-TT. The DNA segment encompassing P919-ET71-VP1-TT was digested with EcoRI, purified from an agarose gel, and cloned into pAM1 at its EcoRI site, to generate the final expression construct pAM1-P919-VP1-TT. After transformation of the recombinant construct into B. pseudocatenulatum M115, it was found that the growth rate of the wild type strain and recombinant strain was 0Á472 AE 0Á18 l h À1 and 0Á463 AE 0Á32 l h À1 respectively, indicating that expression of ET71-VP1 in the presence of P919 promoter and TT did not appreciably alter growth of the host strain.
The presence of recombinant EV71-VP1 protein in B. pseudocatenulatum M115 cell lysate was determined by Western blot analysis using mouse monoclonal antibodies against EV71-VP1. As shown in Fig. 2 , a protein band with a molecular weight of 34 kDa was detected in cellfree extracts from B. pseudocatenulatum M115 containing pAM1-P919-VP1-TT, but was not detected in B. pseudocatenulatum M115 harboring only the pAM1 vector. These results proved that the recombinant B. pseudocatenulatum M115 was able to express EV71-VP1 protein under the control of the constitutive P919 promoter. Furthermore, it was found that pAM-P919-VP1-TT also drove expression of EV71-VP1 in E. coli. This is not surprising as the sequence of P919 is similar to that of the canonical consensus sequence of E. coli promoters (Wang et al. 2012 ). In addition, a ribosome binding site-like sequence (AGGA), which could be recognized by E. coli, was found on the downstream of the P919 sequence. Our results agreed well with previous findings in which P919 was shown to drive the expression of b-glucosidase in both E. coli and B. bifidum (Wang et al. 2012) .
Plasmid stability is one important factor for heterologous protein expression in any bacterial host (Cui et al. 2015) . In our study, pAM1-P919-VP1-TT and pAM1 were independently transformed into B. pseudocatenulatum (1) TCC Gly (G) GGT (5), GGC (4), GGA (3), GGG (7) GGC Val (V) GTA (3), GTC (6), GTG (6), GTT (5) GTG Leu (L) CTA (1), CTC (9), CTG (1), CTT (1), TTA (3), TTG (3) CTG Ala (A) GCA (8), GCC (7), GCG (7), GCT (5) GCC Pro (P) CCA (10), CCC (7), CCG (2) M115. In the absence of the selection of an antibiotic in the culture medium, pAM-P919-VP1-TT was maintained after approximately 160 generations in 80% of the colonies. This stability was comparable to that obtained for the pAM1 vector (83% after 160 generations). This result indicated that the construct has sufficient segregational stability in B. pseudocatenulatum M115, which further suggests the use of this strain as a cell factory for protein production in a variety of applications, especially for the expression of immunogenic antigens for oral immunization.
In conclusion, we successfully constructed a recombinant B. pseudocatenulatum M115 expressing the EV71-VP1 protein under the control of the constitutive P919
promoter. This study supports the concept of using a probiotic candidate (such as B. pseudocatenulatum M115) as a host for heterologous protein expression. The use of synthetic DNA avoids working with real pathogens and, at the same time, allows easy codon usage optimization, which leads to faster, cheaper, and more efficient cloning and expression of genes encoding virulence factors. Further work to determine the immunogenicity of the recombinant B. pseudocatenulatum M115 expressing EV71-VP1 in experimental animals will be challenging.
Materials and methods

Materials, bacterial strains and growth conditions
The bacterial strains, cloning vectors, oligonucleotide primers and the synthetic gene fragments used in this study are listed in Table 2 . B. pseudocatenulatum M115 was cultured in de Man Rogosa and Sharpe (MRS) broth (LAB, Lancashire, UK) supplemented with 0Á25% cysteine (MRSC) in anaerobic jars under anaerobic conditions generated with an oxygen absorber-CO 2 generator system (AnaeroPack-Anaerobe, Mitsubishi, Japan) and incubated at 37°C for 24-48 h. Escherichia coli XL1-Blue was grown at 37°C in Luria-Bertani broth with vigorous shaking. Agarified media were prepared by adding 1Á5% (w/v) bacteriological agar to the corresponding media. For selection, antibiotics were added to the media at the following concentrations, ampicillin at 100 lg ml À1 for E. coli and erythromycin at 2Á5 lg ml À1 for B. pseudocatenulatum.
Codon optimization and gene synthesis
The complete open reading frame of the ET71-VP1 gene with a length of 891 base pairs was retrieved from the database of the National Center for Biotechnology Information (NCBI) (accession no. JF738000Á1). Gene codons were optimized for protein expression in B. pseudocatenulatum based on the Codon Usage Database (http://www. kazusa.or.jp/codon). The codon-optimized ET71-VP1 gene was synthesized as a double-strand DNA fragment by Integrated DNA Technologies (IDT, Singapore). Using the same strategy, the DNA sequence of the constitutive P919 promoter was also synthesized.
General DNA manipulation techniques
General procedures for DNA manipulation were performed as previously described by Sambrook and Russell (2001 
Electroporation
Electrotransformation (electroporation) of E. coli was performed with a Gene Pulser apparatus (Bio-Rad, Hercules, CA) as described by Dower et al. (1988) . The protocol for the preparation of competent cells and the electroporation conditions for B. pseudocatenulatum were in accordance with the methods described by Alvarez-Mart ın et al. (2008) .
Protein expression and verification
A single colony of recombinant B. pseudocatenulatum M115 was inoculated in 10 ml of MRSC medium supplemented with 2Á5 lg ml À1 of erythromycin and incubated at 37°C for 18 h. The bacterial cells were harvested by centrifugation and then transferred into freshly prepared 100 ml MRSC medium supplemented with 2Á5 lg ml À1 of erythromycin and grown at 37°C until an OD 600 of 0Á8 was reached. The bacteria were harvested again and washed twice with phosphate buffer saline (pH 7Á0), and suspended in lysis buffer (0Á5 mol l À1 Na 2 HPO 4 , 5 mol l À1 NaCl, 1 mol l À1 imidazole, 100 mg ml À1 lysozyme, 1 mol l À1 dithiothreitol, and 1X protease inhibitor cocktail) (Amresco, Solon, OH). Bacterial cells were disrupted by vortexing with glass beads in a 1Á5 ml tube for 30 sec. Expression of EV71-VP1 protein was verified by 10% polyacrylamide gel electrophoresis, followed by Western blot analysis. Mouse anti-EV71-VP1 monoclonal antibody (Abnova, Taipei, Taiwan) and goat anti-mouse IgG monoclonal antibody conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Dallas, TX) were used as primary and secondary antibodies respectively. The blot signal was developed by the addition of 1 ml of SuperSignal West Substrate Working Solution (Thermoscience, Carlsbad, CA), and the signal was recorded by the use of a digital camera (Image Quant TM LAS 4000, Uppsala, Sweden).
Plasmid stability
To study the segregational stability of pAM1-P919-VP1-TT expression vector in B. pseudocatenulatum M115, transformants carrying this construct were grown in MRSC broth without erythromycin for approximately 160 generations. Every 20 generations, an aliquot of the culture was removed, diluted, and plated onto antibiotic-free MRSC medium. One hundred colonies were selected and then replicated on MRS agar with and without erythromycin. Colonies grown on MRSC agar with and without antibiotics were counted, and the stability (S) was calculated as follows: S = (N A /N NA ) 9 100, where N A and N NA is the number of colonies growing on MRSC plates with and without erythromycin respectively.
